<DOC>
	<DOCNO>NCT03040726</DOCNO>
	<brief_summary>The goal clinical research study learn netupitant/palonosetron help decrease chronic nausea vomit patient cancer . The safety study drug also study . Some participant receive study drug receive placebo . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect .</brief_summary>
	<brief_title>Netupitant Palonosetron ( AKYNZEO ) Chronic Nausea Vomiting Cancer Patients</brief_title>
	<detailed_description>For participant , find eligible take part study , complete questionnaire nausea/vomiting symptom . These questionnaire take 20 minute complete . Study Drug Administration : If still eligible take part study , randomly assign ( roll dice ) 1 2 group . This do one know one study group well , , bad group . You 2 3 chance assign netupitant/palonosetron group . You take 1 capsule netupitant/palonosetron/placebo mouth Days 1 , 6 , 11 . You report time take dos study staff . For Day 1 dose , know receive study drug placebo . For Days 6 11 dos , neither study staff know receive study drug placebo . However , need safety , study staff able find receiving . You take Day 1 dose clinic home . The Days 6 11 dos may mail separately take instructed study staff . You give patient diary keep track daily nausea , vomit , rescue nausea medication Days 1-15 . You complete end day go sleep . Length Study : You may take study drug/placebo Day 11 . You longer able take study drug/placebo intolerable side effect occur unable follow study direction . Your participation study last visit/call . There also optional 10-day extension describe . Study Visits/Calls : On Day 4 ( +/- 1 day ) , research staff call ask level nausea past 24 hour feel nausea vomit last 12 hour . This information would record patient diary . This call last 10 minute . On Day 10 ( +/- 2 day ) , research staff call ask level nausea vomit past 5 day , symptom past 24 hour , side effect take study drug placebo . This call last 15 minute . On Day 15 ( +/- 2 day ) , complete questionnaire nausea/vomiting symptom , side effect , opinion whether receive study drug placebo , opinion take part study . These questionnaire take 20 minute complete . If unable return clinic , research staff call ask answer question phone . This investigational study . Netupitant/palonosetron FDA approve commercially available help prevent short-term nausea vomit . Giving patient chronic nausea vomit investigational . The study doctor explain study drug design work . Up 42 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>1 . Diagnosis cancer evidence active disease 2 . Chronic nausea past 4 week 3 . Average nausea numeric rating scale &gt; /=4/10 past 24 hour screen 4 . Outpatient MD Anderson Cancer Center 5 . Karnofsky performance status &gt; /=50 % 6 . Age 18 old 7 . Able complete study assessment , include keep daily diary 1 . Delirium ( i.e . Memorial Delirium Rating Scale &gt; 13 ) 2 . Clinical evidence bowel obstruction time study enrollment 3 . Expected use 5HT3 antagonist NK1 antagonist study 4 . Continuation overthecounter therapy nausea and/or vomit study 5 . On cytotoxic chemotherapy high/moderate/low emetogenic risk category oral antineoplastic agent high moderate emetogenic risk category accord late NCCN guideline within 2 week study enrollment 6 . On scheduled potent CYP3A4 inducer time study enrollment ( e.g . avasimibe , carbamazepine , phenytoin , rifampin ) 7 . On scheduled CYP3A4 substrates narrow safety range time study enrollment ( e.g. , alfentanil , astemizole , cisapride , cyclosporine , dihydroergotamine , ergotamine , pimozide , quinidine , sirolimus , tacrolimus , terfenadine ) 8 . On schedule strong moderate CYP3A4 inhibitor ( e.g. , boceprevir , clarithromycin , conivaptan , indinavir , itraconazole , ketoconazole , lopinavir/ritonavir , mibefradil , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telaprevir , telithromycin , voriconazole ; amprenavir , aprepitant , atazanavir , ciprofloxacin , darunavir/ritonavir , diltiazem , erythromycin , fluconazole , fosamprenavir , grapefruit juice , imatinib , verapamil ) within one week study enrollment 9 . Unwilling provide inform consent 10 . Severe renal impairment ( calculated Creatinine clearance &lt; =29 cc/min ) 11 . Severe liver impairment ( ChildPugh Score &gt; 9 ) 12 . Females pregnant , lactating , intend become pregnant participation study ; childbearing age woman birth control . Positive pregnancy test woman childbearing potential , define intact uterus ovary , history menses within last 12 month . Pregnancy test perform day enrollment . In case woman elevate bHCG , candidate eligible participate long level bHCG consistent pregnancy nonpregnant status confirm Gynecologic examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>In situ neoplasm</keyword>
	<keyword>Malignant neoplasms independent ( primary ) multiple site</keyword>
	<keyword>Symptoms sign involve digestive system abdomen</keyword>
	<keyword>Chronic nausea vomit</keyword>
	<keyword>Netupitant/Palonosetron</keyword>
	<keyword>NEPA</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sugar pill</keyword>
	<keyword>Symptom questionnaire</keyword>
	<keyword>Surveys</keyword>
	<keyword>Pill diary</keyword>
	<keyword>Akynzeo</keyword>
</DOC>